Sun Pharma declines over 3.5% on weak earnings
Sun Pharma’s consolidated revenue for the quarter came in at Rs 6,167 crore, posting 23% yoy decline. EBITDA for the quarter fell by 53.2% yoy to Rs 1,400 crore. The company reported a net loss of Rs 321 crore as against net profit of Rs 2,268 crore in Q1FY17. This was due to one-time exceptional provisions Rs 950 crore on account of settlements with Apotex Corporation and retail purchasers.
Sun Pharma was trading at Rs 437.90 per share, down by Rs 437.90 or 2.97% as at 0918 hours on Monday, on the BSE. The stock attracted a traded volume of 19,82,456 shares and traded value of Rs 8,693.66 lakh on the NSE.
Sun Pharmaceuticals Industries Ltd is currently trading at Rs 452.9, up by Rs 1.6 or 0.35% from its previous closing of Rs 451.3 on the BSE.
The scrip opened at Rs 435 and has touched a high and low of Rs 456.7 and Rs 433.15 respectively. So far 7213234(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 108280.69 crore.
The BSE group ‘A’ stock of face value Rs 1 has touched a 52 week high of Rs 833 on 10-Aug-2016 and a 52 week low of Rs 445.05 on 11-Aug-2017. Last one week high and low of the scrip stood at Rs 513.2 and Rs 445.05 respectively.
The promoters holding in the company stood at 54.38 % while Institutions and Non-Institutions held 32.6 % and 13.01 % respectively.